# FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer

> **NCT01358812** · PHASE2 · COMPLETED · sponsor: **Gruppo Oncologico del Nord-Ovest** · enrollment: 37 (actual)

## Conditions studied

- Metastatic Colo-rectal Cancer

## Interventions

- **DRUG:** FOLFOXIRI + Panitumumab

## Key facts

- **NCT ID:** NCT01358812
- **Lead sponsor:** Gruppo Oncologico del Nord-Ovest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-10
- **Final completion:** —
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2015-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01358812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01358812, "FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01358812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*